Core Insights - WuXi Biologics reported a 16.1% year-on-year revenue growth in the first half of 2025, reaching 9.95 billion yuan, with net profit attributable to shareholders increasing by 56.1% to 2.34 billion yuan [1] - Adjusted net profit grew by 6.2% year-on-year to 2.39 billion yuan, aligning with expectations, while the overall gross margin improved by 3.7 percentage points to 42.7% [1] Revenue Breakdown - IND pre-service revenue surged by 35.2% year-on-year to 4.15 billion yuan in the first half of 2025 [2] - Early-stage project revenue declined by 29.7% due to large projects transitioning to later development stages, while Phase III and commercial project revenue increased by 24.9% [2] - Revenue from the U.S. grew by 20.1%, accounting for 60.5% of total revenue, while Europe and China saw revenue growth of 5.7% and a decline of 8.5%, respectively [2] Project Pipeline - The company added 86 new projects in the first half of 2025, with over half coming from the U.S. and an improved contribution from China [3] - The total project count reached 864, including 67 Phase III projects and 24 commercial projects, indicating potential for future revenue growth [3] - Adjusted net profit forecasts for 2025 and 2026 were revised down to 4.90 billion yuan and 5.50 billion yuan, respectively, with a new forecast for 2027 set at 6.34 billion yuan [3]

Investment Rating - The report maintains a "Buy" rating for Wuxi Biologics [5][17][28] Core Insights - Wuxi Biologics reported a revenue of Rmb 9.95 billion for the first half of 2025, representing a year-on-year growth of 16.1%, and a net profit of Rmb 2.34 billion, which is a 56.1% increase year-on-year [8][14] - The adjusted net profit reached Rmb 2.39 billion, reflecting a 6.2% year-on-year growth, aligning with expectations [8][14] - The blended gross margin increased by 3.7 percentage points to 42.7%, while the adjusted net profit margin rose by 1.2 percentage points to 45.6% [8][14] Revenue Breakdown - Pre-IND service revenue grew by 35.2% year-on-year to Rmb 4.15 billion in the first half of 2025 [9][15] - Revenue from early-phase projects (Phase I & II) declined by 29.7% year-on-year, primarily due to large projects moving to later stages [9][15] - Revenue from Phase III and commercial projects increased by 24.9% year-on-year [9][15] - Revenue from the US market grew by 20.1%, accounting for 60.5% of total revenue, while revenue from Europe and China increased by 5.7% and decreased by 8.5%, respectively [9][15] Order Backlog - The total backlog reached US$ 20.4 billion, a 1.2% year-on-year increase, including a service backlog of US$ 11.4 billion (down 13% year-on-year) and potential milestone fees backlog of US$ 9.0 billion (up 27% year-on-year) [9][15] - The backlog within three years increased by 16% year-on-year to US$ 4.2 billion, representing 21% of the total backlog [9][15] Project Pipeline - The number of new projects added in the first half of 2025 was 86, with over 50% from the US [10][16] - The total number of integrated projects reached 864, including 67 Phase III and 24 commercial projects, indicating potential future revenue growth [10][16] Financial Forecasts - Adjusted net profit forecasts for 2025 and 2026 have been revised down to Rmb 4.90 billion and Rmb 5.50 billion, respectively, with a new forecast of Rmb 6.34 billion for 2027 [10][17] - Revenue projections for 2025, 2026, and 2027 are Rmb 21.38 billion, Rmb 24.64 billion, and Rmb 28.57 billion, respectively, with year-on-year growth rates of 14.49%, 15.23%, and 15.95% [12][19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 茲提述(1)藥明合聯招股章程；及(2)本公司日期為二零二四年三月三十一日的 公告，內容有關（其中包括）日期為二零二三年十一月三日的二零二三年連接 子及有效載荷主服務協議，就連接子及有效載荷向藥明合聯集團提供研發及 製造服務，並向藥明合聯集團供應其ADC CRDMO服務使用的相關中間產品。 在行業快速擴張的推動下，市場對本集團ADC CRDMO服務的需求持續大幅 增長。預計對藥明合聯集團服務的需求將進一步增長，因其業務於二零二五 年繼續呈上升態勢。考慮到藥明合聯的強勁表現及藥明合聯集團於截至二零 二五年六月三十日止六個月的最近期未經審核簡明綜合中期業績，預計二零 二三年連接子及有效載荷主服務協議的交易金額於二零二五年將超過其原 定年度上限，因此，建議就二零二三年連接子及有效載荷主服務協議採納經 修訂年度上限。此外，由於二零二三年連接子及有效載荷主服務協議將於二 零二五年十二月三十一日到期，藥明合聯建議訂立 ...

Core Viewpoint - In H1 2025, WuXi Biologics achieved revenue of 9.95 billion yuan, with a year-on-year growth of 16.1%, and a continuous operating income growth of 20.2%, exceeding the company's previous annual guidance [1][2][7] - The company signed 86 new projects, a historical high, with a total of 864 projects in hand, showcasing its leading position in the industry [1][3][7] - The company is expected to continue its rapid growth in 2025 due to comprehensive improvements in technology platforms, production bases, operational efficiency, and global development [1][7] Financial Performance - The company reported a gross profit of 4.25 billion yuan, a year-on-year increase of 27.0%, and a net profit attributable to shareholders of 2.34 billion yuan, up 56.0% [2][7] - Adjusted net profit reached 2.84 billion yuan, reflecting an 11.6% year-on-year growth [2] - The company raised its full-year revenue guidance from 12%-15% to 14%-16% based on H1 performance [2] Project Pipeline - The company has a total of 864 projects, including 429 preclinical projects, 259 phase I projects, 85 phase II projects, 67 phase III projects, and 24 commercial projects [3] - The company signed 9 new projects under the "Winning Molecules" strategy, including 2 phase III projects [3] - The backlog of uncompleted orders totals 20.3 billion USD, with 11.35 billion USD in service orders and 9.0 billion USD in potential milestone orders [2][3] Regional Performance - North America accounted for 60.5% of revenue in H1 2025, with a year-on-year growth of 20.1% [3] - European revenue grew by 5.7%, making up 19.8% of total revenue, while revenue from China decreased by 8.5% to 13.0% of total revenue [3] - Other regions, including Japan and South Korea, saw a significant revenue increase of 136.1% [3] Capacity and Technology Development - The company has established 5 research service centers, 8 drug development centers, and 8 commercial production centers globally, with a planned capacity of approximately 500,000 liters [4] - The company is advancing its production capabilities in various locations, including successful commercial production in Ireland and ongoing capacity optimization in the U.S. [4][5] - The company is developing next-generation high-throughput formulation platforms to meet diverse customer needs [5][6] Future Outlook - The company is positioned as a global leader in the biopharmaceutical CRDMO sector, with expectations for continued growth driven by overseas demand recovery and domestic market improvements [7] - The company anticipates further increases in profit margins due to operational efficiency improvements and rising capacity utilization [7] - The company projects revenues of 21.5 billion yuan, 25.26 billion yuan, and 30.03 billion yuan for 2025-2027, with corresponding growth rates of 15%, 18%, and 19% [7]

Core Insights - The company achieved a revenue of 9.953 billion yuan in H1 2025, representing a year-on-year growth of 16.08% and a net profit of 2.339 billion yuan, up 56.05% [1] - The adjusted net profit reached 2.840 billion yuan, with a growth of 11.60%, and a gross margin of approximately 42.73%, an increase of about 3.6 percentage points year-on-year [1] - The company raised its full-year revenue guidance for 2025 to a growth range of 14%-16% [1] Financial Performance - The company’s net profit forecasts for 2025-2027 are adjusted to 4.578 billion yuan, 5.126 billion yuan, and 6.288 billion yuan respectively, with original estimates being 4.256 billion yuan and 4.995 billion yuan [1] - The earnings per share (EPS) are projected to be 1.1 yuan, 1.3 yuan, and 1.5 yuan for 2025-2027 [1] - The current stock price corresponds to price-to-earnings (PE) ratios of 26.7, 23.9, and 19.5 for the respective years [1] Business Segments - The preclinical business generated revenue of 4.147 billion yuan in H1 2025, showing a year-on-year increase of approximately 35.2% [2] - Clinical III phase and commercialization revenue reached about 4.289 billion yuan, up 24.9%, driven by early projects maturing and existing commercial projects ramping up [2] - The company has a total of 864 projects, with 429 in preclinical/I phase, 259 in II phase, 85 in III phase, and 24 in commercialization as of June 2025 [2] Global Expansion - The company is enhancing its global capacity with 5 research service centers, 8 drug development centers, and 8 commercial production centers worldwide [2] - Revenue growth rates for North America, Europe, China, and other regions were 20.1%, 5.7%, -8.5%, and 136.1% respectively, indicating robust growth in North America [2] - The company’s Irish base has received EMA approval for its first product for commercial production, and the construction of the MFG11 capacity in the U.S. is ongoing [2]

Core Viewpoint - WuXi Biologics (02269) experienced a 2.1% decline in stock price, trading at 32.58 HKD per share with a transaction volume of 304 million HKD as of 09:46 on August 26 [1] Group 1: Company Overview - WuXi Biologics is a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - The company held a 48% market share in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2: Financial Performance - As of the mid-year report in 2025, WuXi Biologics reported total revenue of 9.953 billion CNY and a net profit of 2.339 billion CNY [2]

Core Viewpoint - Goldman Sachs raised its earnings per share forecast for WuXi Biologics (2269.HK) for the years 2023 to 2027 by 11.9% to 15.9%, reflecting better-than-expected gross margin improvement [1] Group 1 - Target price increased from HKD 25.6 to HKD 29.3, maintaining a price-to-earnings ratio target of 23 times, with a neutral rating [1] - The company's mid-term gross margin expanded by 3.6 percentage points to 42.7%, driven by reduced employee stock compensation, increased milestone revenue recognition from R&D, and improved utilization of new capacity, offsetting losses from the Ireland project [1] - Management expects gross margin improvement to continue in the second half of the year, based on operational enhancements and increased capacity utilization, with a long-term gross margin target of 50%, and the Singapore facility's gross margin expected to reach approximately 45% [1]

Group 1 - The core viewpoint of the article is that Jefferies has raised its revenue and net profit forecasts for WuXi Biologics (02269) for the years 2025 to 2027, indicating a positive outlook for the company's growth [1] - Revenue forecast has been adjusted upwards by 0% to 4%, while net profit forecast has been increased by 0% to 7% [1] - The gross margin is expected to rise from 28.5% in 2024 to 30.8% in 2027 [1] Group 2 - Jefferies has raised the target price for WuXi Biologics from HKD 34.8 to HKD 42.6, maintaining an outperform rating [1] - The profitability and valuation of the Contract Research Organization (CRO) industry are sensitive to changes in the funding environment [1] - The potential interest rate cuts in the US in the second half of the year are expected to enhance market preference for the CRO sector [1] Group 3 - It is anticipated that global biotech companies will increase R&D investments in a more favorable funding environment from the second half of this year into next year [1] - Pharmaceutical companies are also expected to expand R&D spending to alleviate patent barrier pressures, which will continue to benefit WuXi Biologics [1]

Core Viewpoint - The report from Citi indicates that WuXi Biologics (02269) is expected to accelerate growth again between 2025 and 2027, with revenue forecasts raised by 0% to 4% and net profit forecasts increased by 0% to 7% [1] Group 1: Financial Projections - Gross margin is projected to improve from 28.5% in 2024 to 30.8% in 2027 [1] - The target price for the company has been raised from HKD 34.8 to HKD 42.6, maintaining an outperform rating [1] Group 2: Industry Insights - The profitability and valuation of the Contract Research Organization (CRO) industry are sensitive to changes in the funding environment [1] - A potential interest rate cut in the US in the second half of the year is expected to enhance market preference for the CRO sector [1] - Global biotech companies are anticipated to increase R&D investments in a more favorable funding environment, while pharmaceutical companies will also expand R&D spending to alleviate patent barrier pressures, benefiting WuXi Biologics [1]

Investment Rating - The investment rating for WuXi Biologics (02269.HK) is "Buy" (maintained) [4][13] Core Views - The company achieved a robust revenue growth of 16.08% year-on-year in H1 2025, with total revenue reaching 9.953 billion yuan and a net profit of 2.339 billion yuan, reflecting a significant increase of 56.05% [4] - The company has raised its full-year revenue guidance for 2025 to a growth range of 14%-16%, supported by a backlog of unfulfilled orders amounting to approximately 20.34 billion USD [4] - The report highlights the strong growth momentum in preclinical services and anticipates future growth in CMO (Contract Manufacturing Organization) business [5] Financial Performance - In H1 2025, the company reported a gross margin of approximately 42.73%, an increase of about 3.6 percentage points year-on-year [4] - The adjusted net profit for H1 2025 was 2.840 billion yuan, representing a year-on-year growth of 11.60% [4] - The company’s earnings per share (EPS) for 2025-2027 are projected to be 1.1, 1.3, and 1.5 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 26.7, 23.9, and 19.5 times [4] Business Growth and Strategy - The preclinical business achieved revenue of 4.147 billion yuan in H1 2025, marking a year-on-year growth of approximately 35.2% [5] - The company has a total of 864 projects in various stages, with 429 in preclinical, 259 in Phase I, 85 in Phase II, 67 in Phase III, and 24 in commercialization [5] - WuXi Biologics is expanding its global capacity with five research service centers, eight drug development centers, and eight commercial production centers [6] Regional Performance - Revenue growth in North America was robust at 20.1%, while Europe and China saw growth rates of 5.7% and a decline of 8.5% respectively [6] - The company’s strategic expansion in North America is expected to continue driving revenue growth [6]